NRx Pharmaceuticals (NRXP) Competitors $2.92 -0.23 (-7.17%) As of 12:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends NRXP vs. GNLX, IFRX, CRBU, CHRS, DRUG, TCRX, RENB, TSVT, NVCT, and CDTXShould you be buying NRx Pharmaceuticals stock or one of its competitors? The main competitors of NRx Pharmaceuticals include Genelux (GNLX), InflaRx (IFRX), Caribou Biosciences (CRBU), Coherus BioSciences (CHRS), Bright Minds Biosciences (DRUG), TScan Therapeutics (TCRX), Renovaro (RENB), 2seventy bio (TSVT), Nuvectis Pharma (NVCT), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. NRx Pharmaceuticals vs. Genelux InflaRx Caribou Biosciences Coherus BioSciences Bright Minds Biosciences TScan Therapeutics Renovaro 2seventy bio Nuvectis Pharma Cidara Therapeutics Genelux (NASDAQ:GNLX) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation, earnings and community ranking. Is GNLX or NRXP more profitable? NRx Pharmaceuticals' return on equity of 0.00% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% NRx Pharmaceuticals N/A N/A -449.16% Which has more risk & volatility, GNLX or NRXP? Genelux has a beta of -1.68, suggesting that its share price is 268% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.08, suggesting that its share price is 8% more volatile than the S&P 500. Do institutionals & insiders hold more shares of GNLX or NRXP? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 9.3% of Genelux shares are owned by company insiders. Comparatively, 19.0% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer GNLX or NRXP? In the previous week, NRx Pharmaceuticals had 7 more articles in the media than Genelux. MarketBeat recorded 9 mentions for NRx Pharmaceuticals and 2 mentions for Genelux. Genelux's average media sentiment score of 1.33 beat NRx Pharmaceuticals' score of 0.35 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate GNLX or NRXP? Genelux presently has a consensus target price of $18.25, suggesting a potential upside of 369.76%. NRx Pharmaceuticals has a consensus target price of $31.67, suggesting a potential upside of 986.34%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20NRx Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Which has better earnings & valuation, GNLX or NRXP? Genelux has higher revenue and earnings than NRx Pharmaceuticals. Genelux is trading at a lower price-to-earnings ratio than NRx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$170K789.34-$28.30M-$0.95-4.09NRx PharmaceuticalsN/AN/A-$30.15M-$2.14-1.36 Does the MarketBeat Community believe in GNLX or NRXP? NRx Pharmaceuticals received 2 more outperform votes than Genelux when rated by MarketBeat users. CompanyUnderperformOutperformGeneluxOutperform Votes14100.00% Underperform VotesNo VotesNRx PharmaceuticalsOutperform Votes16100.00% Underperform VotesNo Votes SummaryNRx Pharmaceuticals beats Genelux on 8 of the 15 factors compared between the two stocks. Get NRx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXP vs. The Competition Export to ExcelMetricNRx PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.00M$6.82B$5.57B$9.07BDividend YieldN/A2.96%5.36%3.98%P/E Ratio-1.359.6487.6617.51Price / SalesN/A343.161,230.2781.58Price / CashN/A65.0944.3037.67Price / Book-2.095.245.094.70Net Income-$30.15M$154.35M$117.51M$224.34M7 Day Performance-1.33%0.20%0.80%-0.68%1 Month Performance88.95%0.85%8.90%3.99%1 Year Performance-92.29%6.58%25.99%18.57% NRx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXPNRx Pharmaceuticals3.0425 of 5 stars$2.92-7.2%$31.67+986.3%-91.8%$35.24MN/A-1.362Analyst ForecastGNLXGenelux1.8418 of 5 stars$3.92-1.0%$18.25+365.6%-62.9%$135.40M$170,000.00-4.1310Positive NewsHigh Trading VolumeIFRXInflaRx2.406 of 5 stars$2.28-2.6%$8.00+250.9%+30.2%$134.25M$70,000.00-2.1160Short Interest ↑CRBUCaribou Biosciences2.627 of 5 stars$1.48-2.0%$10.33+598.2%-77.6%$134.02M$11.48M-0.90100Gap UpCHRSCoherus BioSciences4.0924 of 5 stars$1.16-6.5%$5.38+363.4%-47.0%$133.64M$257.24M-14.50330DRUGBright Minds Biosciences3.7347 of 5 stars$30.03-6.4%$84.33+180.8%+1,467.5%$133.03MN/A-60.06N/AShort Interest ↓TCRXTScan Therapeutics2.7998 of 5 stars$2.45-2.8%$11.25+359.2%-52.3%$130.76M$9.36M-2.31100Short Interest ↓Positive NewsRENBRenovaro0.8283 of 5 stars$0.82-7.5%N/A-82.5%$130.74MN/A-0.8620Short Interest ↑TSVT2seventy bio2.2568 of 5 stars$2.53-2.7%$9.00+255.7%-28.7%$130.52M$45.62M-1.36440NVCTNuvectis Pharma3.6269 of 5 stars$6.73+2.7%$21.00+212.0%-13.7%$130.03MN/A-5.808Gap DownCDTXCidara Therapeutics4.3552 of 5 stars$18.12-4.2%$32.20+77.7%+32.6%$127.75M$63.90M-0.7190Analyst ForecastShort Interest ↑News CoverageGap Down Related Companies and Tools Related Companies Genelux Alternatives InflaRx Alternatives Caribou Biosciences Alternatives Coherus BioSciences Alternatives Bright Minds Biosciences Alternatives TScan Therapeutics Alternatives Renovaro Alternatives 2seventy bio Alternatives Nuvectis Pharma Alternatives Cidara Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NRXP) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NRx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NRx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
